TORONTO, Nov. 29,
2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the
"Company") (TSX: HLS), a pharmaceutical company focusing on central
nervous system and cardiovascular markets, announces that Dr.
Kyle Dempsey has been appointed to
the board of directors of the Company (the "Board") as an
independent director. Dr. Dempsey is a partner at MVM Partners
("MVM"), a healthcare focused private equity fund based in
Boston, Massachusetts and
London, UK.
"Kyle will bring significant additional scientific, business and
investment expertise to the Board, as well as the perspective of
MVM, a significant and long-term healthcare-oriented shareholder,"
said Greg Gubitz, Chairman of HLS.
"This appointment reflects our commitment to building a strong and
diverse board of directors to help the Company execute on its
long-term growth strategy and continue to build shareholder
value."
Dr. Dempsey added, "I am pleased to join the board of directors
of HLS at such an exciting time for the business. The HLS team has
strategically constructed a portfolio of assets focused on the
central nervous system and cardiovascular markets. With continued
commercial execution, the company has significant growth potential,
especially from Vascepa due to its recently expanded reimbursement.
I look forward to helping the Company maximize its potential in
this next stage of its journey."
While at MVM, Dr. Dempsey has led investments and served as a
board director in private and public companies, including
NASDAQ-listed specialty pharmaceutical company Optinose, Inc.
(NASDAQ: OPTN) and GT Medical Technologies, Inc.; he is also an
observer on the board of MDxHealth SA (NASDAQ: MDXH) and was
previously a board observer of Biotheranostics, Inc. (acquired by
Hologic). Prior to MVM, he was a consultant at Bain & Company
where he worked on cases across various healthcare sub-sectors. Dr.
Dempsey has M.D. and M.B.A. degrees from Harvard University and a B.A. in biochemistry from
Bowdoin College.
ABOUT HLS THERAPEUTICS
INC.
Formed in 2015, HLS is a pharmaceutical company focused on the
acquisition and commercialization of late-stage development,
commercial stage promoted and established branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting the central nervous system and cardiovascular therapeutic
areas. HLS's management team is composed of seasoned pharmaceutical
executives with a strong track record of success in these
therapeutic areas and at managing products in each of these
lifecycle stages. For more information, please visit:
www.hlstherapeutics.com
FORWARD LOOKING INFORMATION
This release includes forward-looking statements regarding
HLS and its business. Such statements are based on the current
expectations and views of future events of HLS's management. In
some cases the forward-looking statements can be identified by
words or phrases such as "may", "will", "expect", "plan",
"anticipate", "intend", "potential", "estimate", "believe" or the
negative of these terms, or other similar expressions intended to
identify forward-looking statements, including, among others,
statements with respect to HLS's pursuit of additional product and
pipeline opportunities in certain therapeutic markets, statements
regarding growth opportunities, expectations regarding financial
performance, and the NCIB and ASPP. The forward-looking events and
circumstances discussed in this release may not occur and could
differ materially as a result of known and unknown risk factors and
uncertainties affecting HLS, including risks relating to the
specialty pharmaceutical industry, risks related to the regulatory
approval process, economic factors and many other factors beyond
the control of HLS. Forward-looking statements and information by
their nature are based on assumptions and involve known and unknown
risks, uncertainties and other factors which may cause HLS's actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking statement
or information. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. A
discussion of the material risks and assumptions associated with
this release can be found in the Company's Annual Information Form
dated March 16, 2022, and
Management's Discussion and Analysis dated November 9, 2022, both of which have been filed
on SEDAR and can be accessed at www.sedar.com. Accordingly, readers
should not place undue reliance on any forward-looking statements
or information. Except as required by applicable securities laws,
forward-looking statements speak only as of the date on which they
are made and HLS undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise.
SOURCE HLS Therapeutics Inc.